Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted immune therapies to expand specific CD8 T-cells in vivo, today presented new interim data ...
Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with ...
Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial. This is an ASCO Meeting ...
Collaborative research defines the FOXO1-KLHL6 axis as a novel therapeutic target to enhance T cell-mediated immune response against tumors CD8⁺ T cells are the frontline soldiers of the body against ...
Clonally expanded CD8+ T cells are key drivers of alopecia areata, mediating epithelial cell death and immune infiltration. JAK inhibitors are approved for AA treatment, but recurrence is common, ...
The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.
Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
Background Chronic hepatitis B virus (HBV) infection disproportionately affects people living with HIV, who are often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results